This Phase 2 study saw Better Therapeutics using BT-001 to treat type 2 diabetes. BT-001 is a prescription digital therapeutic that uses nutritional cognitive behavioral therapy (nCBT) to meet its goal.
Better Therapeutics notes that the Phase 2 clinical trial saw a decrease in baseline A1c meeting its primary endpoint. That includes a statistically significant drop when compared to patients taking a placebo.
Frank Karbe, president and CEO of Better Therapeutics, said the following about the clinical trial results.
“We believe the data from this trial is remarkable, given we enrolled a diverse patient population with advanced disease already on rigorous blood sugar lowering regimens and who could self-select their dose of BT-001, unlike in traditional new drug pivotal trials. The positive data from this trial serves as an important stepping stone towards our goal of bringing BT-001 to patients and physicians in need of new therapies, and entering the next phase of our growth as a commercial-stage company.”
BTTX Stock: Better Therapeutics Wants Marketing Approval for BT-001
With those positive results in hand, Better Therapeutics intends to submit a de novo classification request to the U.S. Food and Drug Administration (FDA). It’s aiming to do so in the third quarter of 2022. This has it applying for marketing authorization for BT-001 to treat type 2 diabetes.
The news brings heavy trading to BTTX stock today with some 32 million shares on the move as of this writing. That’s well above its daily average trading volume of around 6.9 million shares.
BTTX stock is up 27.5% as of Thursday morning.
There’s more hot stock market news investors will want to know about below!
InvestorPlace is home to all of the latest stock market news traders need for Thursday! Among that is what has shares of Palantir Technologies (NYSE:PLTR), ChargePoint (NYSE:CHPT) and Altria (NYSE:MO) stock on the move today. You can read more on these matters at the following links!
More Thursday Stock Market News
- What’s Going on With Palantir (PLTR) Stock Today?
- ChargePoint (CHPT) Stock Powers Up on New Climate Deal
- Altria (MO) Stock Slips as Value of Juul Investment Dwindles
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.